Figure 1 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers

Figure 1 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers

<p>Differences in intrinsic subtype classification from baseline to surgery in the POETIC subset and the NeoAI study. Changes of intrinsic subtype classifications in all the POETIC-treated samples (<b>A</b>); in POETIC Luminal B–treated samples (<b>B</b>); in POETIC con...

Descrizione completa

Salvato in:

Dettagli Bibliografici
Autore principale:	Milana A. Bergamino (15038015) (author)
Altri autori:	Gabriele Morani (15038018) (author), Joel Parker (15038021) (author), Eugene F. Schuster (9726535) (author), Mariana F. Leal (15038024) (author), Elena López-Knowles (15038027) (author), Holly Tovey (9360536) (author), Judith M. Bliss (8827107) (author), John F.R. Robertson (15025368) (author), Ian E. Smith (1545553) (author), Mitch Dowsett (645) (author), Maggie C.U. Cheang (14946768) (author)
Pubblicazione:	2025
Soggetti:	Cancer Tumor Biology Cancer Detection and Diagnosis Therapeutic Research and Development Biomarkers Genetic biomarkers Breast Cancer Drug Resistance Novel mechanisms Endocrinology Translational Research
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Figure 2 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
di: Milana A. Bergamino (15038015)
Pubblicazione: (2025)

Figure 3 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
di: Milana A. Bergamino (15038015)
Pubblicazione: (2025)

Figure 4 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
di: Milana A. Bergamino (15038015)
Pubblicazione: (2025)

Figure 5 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
di: Milana A. Bergamino (15038015)
Pubblicazione: (2025)

Figure 6 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
di: Milana A. Bergamino (15038015)
Pubblicazione: (2025)

Supplementary Data from Pharmacological Targeting of Androgen Receptor Elicits Context-Specific Effects in Estrogen Receptor–Positive Breast Cancer
di: Lixuan Wei (14962431)
Pubblicazione: (2025)

Supplementary Table S1 from The EstroGene Database Reveals Diverse Temporal, Context-Dependent, and Bidirectional Estrogen Receptor Regulomes in Breast Cancer
di: Zheqi Li (14961021)
Pubblicazione: (2025)

Supplementary Table S10 from The EstroGene Database Reveals Diverse Temporal, Context-Dependent, and Bidirectional Estrogen Receptor Regulomes in Breast Cancer
di: Zheqi Li (14961021)
Pubblicazione: (2025)

Supplementary Table S11 from The EstroGene Database Reveals Diverse Temporal, Context-Dependent, and Bidirectional Estrogen Receptor Regulomes in Breast Cancer
di: Zheqi Li (14961021)
Pubblicazione: (2025)

Supplementary Table S2 from The EstroGene Database Reveals Diverse Temporal, Context-Dependent, and Bidirectional Estrogen Receptor Regulomes in Breast Cancer
di: Zheqi Li (14961021)
Pubblicazione: (2025)

Supplementary Table S3 from The EstroGene Database Reveals Diverse Temporal, Context-Dependent, and Bidirectional Estrogen Receptor Regulomes in Breast Cancer
di: Zheqi Li (14961021)
Pubblicazione: (2025)

Supplementary Table S4 from The EstroGene Database Reveals Diverse Temporal, Context-Dependent, and Bidirectional Estrogen Receptor Regulomes in Breast Cancer
di: Zheqi Li (14961021)
Pubblicazione: (2025)

Supplementary Table S5 from The EstroGene Database Reveals Diverse Temporal, Context-Dependent, and Bidirectional Estrogen Receptor Regulomes in Breast Cancer
di: Zheqi Li (14961021)
Pubblicazione: (2025)

Supplementary Table S6 from The EstroGene Database Reveals Diverse Temporal, Context-Dependent, and Bidirectional Estrogen Receptor Regulomes in Breast Cancer
di: Zheqi Li (14961021)
Pubblicazione: (2025)

Supplementary Table S7 from The EstroGene Database Reveals Diverse Temporal, Context-Dependent, and Bidirectional Estrogen Receptor Regulomes in Breast Cancer
di: Zheqi Li (14961021)
Pubblicazione: (2025)

Supplementary Table S8 from The EstroGene Database Reveals Diverse Temporal, Context-Dependent, and Bidirectional Estrogen Receptor Regulomes in Breast Cancer
di: Zheqi Li (14961021)
Pubblicazione: (2025)

Supplementary Table S9 from The EstroGene Database Reveals Diverse Temporal, Context-Dependent, and Bidirectional Estrogen Receptor Regulomes in Breast Cancer
di: Zheqi Li (14961021)
Pubblicazione: (2025)

Supplementary Table 1 from Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor–Positive Metastatic Breast Cancers
di: Juliana Navarro-Yepes (17079059)
Pubblicazione: (2025)

Supplementary Table S4 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
di: Andrés Elía (15055031)
Pubblicazione: (2025)

Supplementary Table S5 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
di: Andrés Elía (15055031)
Pubblicazione: (2025)

Supplementary Table S6 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
di: Andrés Elía (15055031)
Pubblicazione: (2025)

Supplementary Table S7 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
di: Andrés Elía (15055031)
Pubblicazione: (2025)

Supplementary Table S8 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
di: Andrés Elía (15055031)
Pubblicazione: (2025)

Supplementary Table S1 from Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer
di: Emil Christensen (15054394)
Pubblicazione: (2025)

Supplementary Table S2 from Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer
di: Emil Christensen (15054394)
Pubblicazione: (2025)

Supplementary Table S1 from Supraphysiological Androgens Promote the Tumor Suppressive Activity of the Androgen Receptor through cMYC Repression and Recruitment of the DREAM Complex
di: Michael D. Nyquist (16918265)
Pubblicazione: (2025)

Supplemental Figures 1-4 from Supraphysiological Androgens Promote the Tumor Suppressive Activity of the Androgen Receptor through cMYC Repression and Recruitment of the DREAM Complex
di: Michael D. Nyquist (16918265)
Pubblicazione: (2025)

Figure S1 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
di: Jamunarani Veeraraghavan (16461809)
Pubblicazione: (2025)

Figure S2 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
di: Jamunarani Veeraraghavan (16461809)
Pubblicazione: (2025)

Figure S3 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
di: Jamunarani Veeraraghavan (16461809)
Pubblicazione: (2025)

Figure S4 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
di: Jamunarani Veeraraghavan (16461809)
Pubblicazione: (2025)

Figure S5 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
di: Jamunarani Veeraraghavan (16461809)
Pubblicazione: (2025)

Figure S6 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
di: Jamunarani Veeraraghavan (16461809)
Pubblicazione: (2025)

Supplementary Tables 1 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
di: Jamunarani Veeraraghavan (16461809)
Pubblicazione: (2025)

Supplementary Data S1 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
di: Andrew A. Davis (15030032)
Pubblicazione: (2025)

Figure S1 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
di: Nicolas A. Giraldo (15050937)
Pubblicazione: (2025)

Figure s2 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
di: Nicolas A. Giraldo (15050937)
Pubblicazione: (2025)

Supplementary Data 1 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
di: Nicolas A. Giraldo (15050937)
Pubblicazione: (2025)

Supplementary Data 2 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
di: Nicolas A. Giraldo (15050937)
Pubblicazione: (2025)

Supplementary Data 3 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
di: Nicolas A. Giraldo (15050937)
Pubblicazione: (2025)

Cannot write session to /tmp/vufind_sessions/sess_0fdesgjclia16vj5ip7p4r29hh